MiNK Therapeutics, Inc. SEC filings INKT

MiNK Therapeutics, Inc. has 265 filings in SEC EDGAR's recent list, going back to Jan 22, 2021. Its latest annual report, Form ARS, was filed on Apr 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Aug 13, 2026 (results of operations). The company's fiscal year ends on December 31.

Form Description Filed Period
DEF 14A Proxy statement Apr 30, 2026 Jun 17, 2026
DEF 14A Proxy statement Apr 30, 2025 Dec 31, 2024
PRE 14A Preliminary proxy statement Apr 18, 2025 Dec 31, 2024
DEF 14A Proxy statement Dec 20, 2024 Jan 17, 2025
PRE 14A Preliminary proxy statement Dec 6, 2024 Jan 17, 2025
DEF 14A Proxy statement Apr 29, 2024 Dec 31, 2023
DEF 14A Proxy statement May 1, 2023 Dec 31, 2022
DEF 14A Proxy statement Apr 29, 2022 Jun 8, 2022

Showing 8 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
INKT (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
New York, NY
SEC filer status
Non-accelerated filer, Smaller reporting company, Emerging growth company
SEC CIK
1840229
Former names
AgenTus Therapeutics, Inc. (until Mar 18, 2021); AgenTus Therapeutics, Inc. (until Mar 18, 2021)

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.